ADHD medications and cardiovascular risk: Some heartening news

JAMA

Volumn 306, Issue 24, 2011, Pages 2723-2724

  Shaw, Philip ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PSYCHOSTIMULANT AGENT;

ANOREXIA; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG SAFETY; DYSPNEA; EDITORIAL; ELECTROCARDIOGRAM; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; PRIORITY JOURNAL; PRODUCT RECALL; SIDE EFFECT; STROKE; SUDDEN DEATH; WEIGHT REDUCTION;

EID: 84555195331     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1866     Document Type: Editorial

References (15)

1. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673-2683.
2. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention- deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120-129.
3. Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry. 2010;71(12):1590-1597.
4. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-247.
5. Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women [published correction appears in Am Heart J. 2010;160(1):208]. Am Heart J. 2010;159(4):612-619, e3.
6. Vetter VL, Elia J, Erickson C, et al. American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423. (Pubitemid 351653546)
7. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992-1001.
8. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/ hyperactivity disorder. Pediatrics. 2007;120(6):e1494- e1501.
9. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009;124(1):e75-e80.
10. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896-1904.
11. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. (Pubitemid 44464584)
12. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195-206.
13. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from theWHOWorld Mental Health Survey Initiative. Occup Environ Med. 2008;65(12):835-842.
14. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee meeting. http://www.fda.gov/ohrms/dockets/ac/06/briefing /2006-4202-00-TOC.htm. Food and Drug Administration Web site. February 9-10, 2006. Accessed November 21, 2011.
15. Nutt DJ, Fone K, Asherson P, et al. British Association for Psychopharmacology. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21(1):10-41. (Pubitemid 46012081)